Detalhe da pesquisa
1.
Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study).
Circ Res
; 121(11): 1279-1290, 2017 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28923793
2.
The Interdisciplinary Stem Cell Institute's Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental Cell Therapy to Patients With Rare Serious Diseases.
Front Cell Dev Biol
; 9: 675738, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34169074
3.
Radiation therapy alone versus radiation therapy plus radiofrequency ablation/vertebral augmentation for spine metastasis: study protocol for a randomized controlled trial.
Trials
; 21(1): 964, 2020 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33228756
4.
Clinical and Neurophysiological Changes after Targeted Intrathecal Injections of Bone Marrow Stem Cells in a C3 Tetraplegic Subject.
J Neurotrauma
; 36(3): 500-516, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29790404
5.
Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
Chest
; 151(5): 971-981, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27890713
6.
Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.
J Am Coll Cardiol
; 69(5): 526-537, 2017 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27856208
7.
Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
J Gerontol A Biol Sci Med Sci
; 72(11): 1513-1522, 2017 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28977399
8.
Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty.
J Gerontol A Biol Sci Med Sci
; 72(11): 1505-1512, 2017 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28444181
9.
Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty.
Oncotarget
; 7(11): 11899-912, 2016 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26933813